Cancer/testis antigen 1 (91-101)

Cancer/testis antigen 1 (91-101) is a synthetic peptide fragment derived from the well-characterized cancer/testis antigen 1 (CTAG1), also known as NY-ESO-1. This nonapeptide represents a specific epitope region within the larger antigen, which is notable for its restricted expression in normal testicular tissue and a broad range of malignancies. Its unique biochemical profile and immunogenic properties have made it a focal point in tumor immunology, epitope mapping, and antigen presentation studies. Researchers value this peptide as a defined tool for dissecting cellular immune recognition mechanisms and for evaluating T cell responses in cancer-related investigations.

Immunological assay development: The 91-101 epitope of CTAG1 serves as a critical reagent for the development and optimization of immunological assays, including ELISPOT, intracellular cytokine staining, and flow cytometry-based detection of antigen-specific T cells. Its defined amino acid sequence allows for precise stimulation of cytotoxic T lymphocytes (CTLs) in vitro, facilitating the quantification and characterization of immune responses against tumor-associated antigens. Utilizing this peptide in assay systems enables researchers to monitor antigen-specific cellular immunity in preclinical models and patient-derived samples, advancing the understanding of tumor immunosurveillance.

Epitope mapping and validation: As a well-defined peptide segment, the 91-101 region is instrumental in mapping T cell epitopes within the CTAG1 protein. Its use in epitope validation studies provides insights into the minimal recognition motifs required for T cell activation. By systematically analyzing T cell responses to this peptide, investigators can delineate the immunodominant regions of the antigen, guiding the rational design of peptide-based vaccines and immunotherapeutic strategies targeting cancer/testis antigens.

Antigen presentation research: The peptide is widely utilized to explore the mechanisms of major histocompatibility complex (MHC) class I antigen processing and presentation. By pulsing antigen-presenting cells with the 91-101 sequence, researchers can investigate peptide loading efficiency, MHC-peptide stability, and subsequent T cell recognition events. These studies contribute to a deeper understanding of how tumor antigens are processed and displayed to the immune system, informing the development of more effective immunomodulatory approaches.

T cell receptor specificity studies: The defined nature of the CTAG1 (91-101) peptide enables its application in evaluating the specificity and avidity of T cell receptors (TCRs) recognizing cancer/testis antigens. By employing this peptide in functional assays, researchers can characterize TCR-peptide-MHC interactions, assess cross-reactivity with related epitopes, and identify high-affinity TCRs suitable for adoptive cell transfer protocols in experimental settings. Such studies provide essential data for the engineering of T cells with enhanced anti-tumor activity.

Peptide-based screening platforms: The 91-101 peptide is a valuable component in high-throughput screening platforms designed to identify novel immunomodulatory compounds or antibodies that interact with CTAG1-derived epitopes. Incorporation of this peptide into multiplexed arrays or binding assays allows for the systematic evaluation of candidate molecules that may modulate antigen-specific immune responses. This application supports the discovery and preclinical validation of next-generation immunotherapeutic agents in oncology research.

1. Constitutive and inflammation-dependent antimicrobial peptides produced by epithelium are differentially processed and inactivated by the commensal Finegoldia magna and the pathogen Streptococcus pyogenes

2. Sex differences in oxidative stress level and antioxidative enzymes expression and activity in obese pre-diabetic elderly rats treated with metformin or liraglutide

3. The spatiotemporal control of signalling and trafficking of the GLP-1R

4. Emu oil in combination with other active ingredients for treating skin imperfections

5. Emerging applications of nanotechnology for diagnosis and therapy of disease: a review